- Pfizer CEO Albert Bourla announced that major pharmaceutical companies are ready to work with the Trump administration to make medicines more affordable and directly available to consumers.
- This move comes after Trump demanded that 17 drugmakers expand direct-to-consumer options and lower prices to match those in other industrialized countries, threatening to use “every tool” if they did not comply.
- Pfizer and Bristol Myers Squibb have already revealed plans to offer their blood thinner Eliquis at a lower price online, building on Pfizer's existing direct-to-consumer telehealth and prescription services.
- Other companies, such as Eli Lilly and Novo Nordisk, are also exploring direct access for their obesity drugs, aiming to bypass pharmacy benefit managers.
- Despite potential sector-specific tariffs on pharmaceutical imports, which could escalate to 250 percent, Pfizer expects to meet its financial forecasts, though experts have refuted Trump's claims of significant drug price reductions.
IN FULL
